▽The New England Journal of Medicine: Research & Review Articles on Diseases & Clinical Practice ●04/18 05:24 Feb 07, 2025CMEObinutuzumab in Active Lupus NephritisR.A. Furie and OthersIn this trial, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, plus standard therapy provided significantly better renal responses than standard therapy alone in patients with lupus nephritis.Editorial To B or Not to B — the Role of B-Cell Depletion in Lupus NephritisImages in Clinical MedicineApr 12,
▽Journal of Clinical Oncology ●04/17 22:43 ORIGINAL REPORTS Apr 16, 2025Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non–Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834Satoru Miura et al.Partial AccessEDITORIALS Apr 16, 2025Can Improving Adjuvant Endocrine Therapy Persistence Improve Survival Outcomes for Patients With Early-Stage Breast Cancer?Megan E.